Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank83
3Y CAGR+163.1%
5Y CAGR+32.6%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+163.1%/yr
vs -54.2%/yr prior
5Y CAGR
+32.6%/yr
Recent acceleration
Acceleration
+217.3pp
Accelerating
Percentile
P83
Within normal range
vs 5Y Ago
4.1x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $102.68M | -12.8% |
| 2024 | $117.72M | +101.2% |
| 2023 | $58.51M | +938.1% |
| 2022 | $5.64M | +8.4% |
| 2021 | $5.20M | -79.2% |
| 2020 | $25.05M | +4106.9% |
| 2019 | $595449.00 | -99.5% |
| 2018 | $127.92M | - |
| 2017 | $0.00 | - |
| 2016 | $0.00 | - |